Back to search results

Observational Study of Voyager DSLT for Glaucoma

This study is looking at how a treatment called Voyager DSLT (Direct Selective Laser Trabeculoplasty) affects the daily changes in eye pressure (intraocular pressure or IOP) in people with primary open-angle glaucoma (POAG). You might be able to join if you are 18 or older, have POAG, and are currently using 1 to 3 eye pressure-lowering medications. The study will measure your eye pressure at different times of the day before and 6 months after the DSLT treatment to see if the daily fluctuations in pressure change. The study aims to enroll 40 participants.

Study design
This is an observational study, meaning researchers will watch what happens without assigning different treatments. It will involve 40 participants at one location.
What's involved
You would have a screening visit, a baseline visit where the DSLT treatment is performed, and a follow-up visit 6 months later. Your eye pressure will be measured at specific times during the baseline visit.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months after the DSLT treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07428668

Change in IOP Fluctuation After DSLT

Recruiting
Not specifiedAges 18+Observational
Ophthalmology Associates, Fort Worth
~40 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:Voyager DSLT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in diurnal intraocular pressure (IOP) fluctuation
Measured over Measured at baseline and at 6 months post-DSLT treatment

Conditions

Glaucoma

Explore related trials

Glaucoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Brian Flowers, MD · PRINCIPAL_INVESTIGATOR · Ophthalmology Associates

Who to contact

Kaitlin Sinclair
[email protected]
(817)332-2020
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject status as follows:
Diagnosis of OAG (i.e., primary, pseudoexfoliation, or pigmentary glaucoma) of any severity or OHT in the study eye (i.e., eye to undergo surgery).
IOP-lowering medication regimen in the study eye as follows:
Angle anatomy in the study eye defined as follows:
Medicated mean diurnal IOP (based on 8AM, 10AM and 4PM assessments) of ≥ 16 mmHg and less than or equal to 30 mmHg.
Able and willing to attend scheduled follow-up exams for 6 months post-operatively.
Successful DSLT treatment.

Exclusion

Status in the study eye as follows:
Unable to provide an adequate and interpretable visual field examination result (i.e., fixation losses, false positives and false negatives must all be less than 33%) in the study eye.
Vertical C/D ratio \> 0.8 in the study eye.
Presence of retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.
Corneal status in the study eye as follows:
Lens status in the study eye:
Choroidal detachment, effusion, choroiditis, neovascularization, or any active choroidopathy.
Retinal or optic nerve disorders in either eye, either degenerative or evolutive, that are not associated with the existing glaucoma condition, including proliferative diabetic retinopathy (mild background diabetic retinopathy permissible), central retinal artery occlusion, central retinal vein occlusion, wet age-related macular degeneration, advanced dry age-related macular degeneration, (e.g., presence of numerous large drusen associated with disturbance to or elevation of the retinal pigment epithelium), significant retinal pigment epithelial changes or optic atrophy.
Other ocular status in the study eye as follows:
Fellow eye status as follows:
Subject status as follows:

What this trial measures

  • Change in diurnal intraocular pressure (IOP) fluctuationMeasured at baseline and at 6 months post-DSLT treatment